Eli Lilly and Company (NYSE:LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
What To Know: After the market close on Friday, Eli Lilly announced FDA approval of Zepbound (tirzepatide) as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity.
Obstructive sleep apnea is estimated to affect 50 million to 80 million people in the U.S., with an estimated 20 million suffering from moderate-to-severe forms. Clinical trials demonstrated the drug's efficacy, with nearly half of patients on the highest dose showing significant improvement in their apnea-hypopnea index, a primary diagnostic metric.
"Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity."
The approval is expected to impact insurance coverage for Zepbound, potentially expanding Medicare benefits for obesity-related treatments. In addition to improved obstructive sleep apnea symptoms, adults on Zepbound lost an average of 45 lbs (18%) of their body weight in Phase 3 trials.
The approval also positions Eli Lilly ahead of competitors like Novo Nordisk, whose Wegovy lacks approval for sleep apnea. The company's ongoing $3 billion investment in manufacturing capacity underscores its focus on meeting demand for its diabetes and obesity treatments.
Eli Lilly reported third-quarter revenue of $11.44 billion in October, reflecting a 20% year-over-year increase. Zepbound accounted for approximately $1.26 billion in total revenue during the quarter.
LLY Price Action: Eli Lilly shares were up 3.11% at $791.63 at the time of writing, according to Benzinga Pro.
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
"Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," said 
「今日、多くの閉塞性睡眠時無呼吸症のケースは診断されず治療されておらず、何百万人もの人々が深刻な健康への影響を受けるリスクにさらされています」と、リリーの心血管代謝健康部門のエグゼクティブバイスプレジデント兼リリー米国の社長であるパトリック・ジョンソンは述べました。「ゼップバウンドは、中等度から重度の閉塞性睡眠時無呼吸症を大幅に改善し、肥満の成人の長期的な体重減少を助ける最初の薬です。」
